-
1.
公开(公告)号:WO2022159955A1
公开(公告)日:2022-07-28
申请号:PCT/US2022/070259
申请日:2022-01-20
申请人: THE SCRIPPS RESEARCH INSTITUTE , BOLLONG, Michael , SCHULTZ, Peter , SHAO, Sida , CHATTERJEE, Arnab , CHEN, Jian , ZHANG, Nan
发明人: BOLLONG, Michael , SCHULTZ, Peter , SHAO, Sida , CHATTERJEE, Arnab , CHEN, Jian , ZHANG, Nan
IPC分类号: C07D207/16 , C07D487/04 , A61P11/00 , A61K31/401
摘要: The present disclosure relates to compounds, and to their pharmaceutical compositions, that inhibit dipeptidyl peptidase IV (DPP4). The compounds selectively promote the proliferation of alveolar type 2 cells (AEC2s) and are useful in therapeutic methods of treating diseases whose etiology, for example, derives from epithelial degeneration and maladaptive remodeling, such as pulmonary diseases like idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), and infant respiratory distress syndromes (IRDS).
-
公开(公告)号:WO2022113814A1
公开(公告)日:2022-06-02
申请号:PCT/JP2021/042017
申请日:2021-11-16
申请人: JSR株式会社
IPC分类号: C07C65/10 , C07C309/12 , C07C309/17 , C07C381/12 , C07D207/16 , C07D211/60 , C07D211/62 , C07D327/06 , C07D333/76 , C07D405/12 , C07D491/113 , C09K3/00 , G03F7/004 , G03F7/038 , G03F7/039 , G03F7/20
摘要: 感度やLWR性能、CDU性能を十分なレベルで発揮可能な感放射線性樹脂組成物、パターン形成方法及びオニウム塩化合物を提供する。下記式(1)で表されるオニウム塩化合物と、酸解離性基を有する構造単位を含む樹脂と、溶剤とを含む感放射線性樹脂組成物。 (上記式(1)中、R1は、炭素数1~20の1価の炭化水素基である。R2及びR3は、それぞれ独立して、炭素数1~20の1価の炭化水素基であるか、又はR2とR3とが互いに合わせられこれらが結合する炭素原子とともに構成される環員数3~20の環状構造を表す。R4は、水素原子若しくは炭素数1~20の1価の炭化水素基であり、かつL1は、炭素数1~40の置換又は非置換の2価の連結基であるか、又はR4とL1とは互いに合わせられこれらが結合する窒素原子とともに構成される環員数3~20の複素環構造を含む基を表す。L2は、単結合又は炭素数1~40の置換又は非置換の2価の連結基である。Rf1及びRf2は、それぞれ独立して、水素原子、フッ素原子、炭素数1~10の1価の炭化水素基又は炭素数1~10の1価のフッ素化炭化水素基である。Rf1及びRf2がそれぞれ複数存在する場合、複数のRf1及びRf2は互いに同一又は異なる。nは1~4の整数である。Z+は、1価の感放射線性オニウムカチオンである。)
-
公开(公告)号:WO2022112351A1
公开(公告)日:2022-06-02
申请号:PCT/EP2021/082864
申请日:2021-11-24
申请人: BASF SE
发明人: ZIMMERMANN, Gunther , KORDES, Markus , SEISER, Tobias , HEINRICH, Marc , KRAEMER, Gerd , SEITZ, Thomas , NEWTON, Trevor William
IPC分类号: C07D207/16 , C07D305/06 , C07D307/16 , C07D307/28 , C07D309/28 , C07D317/32 , C07D327/04 , C07D493/18 , A01N43/08 , A01N43/16 , A01N43/20 , A01N43/28 , A01N43/36
摘要: The present invention relates to malonamide compounds of the formula (I) wherein the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of said malonamide compounds or the corresponding compositions for controlling unwanted vegetation. Furthermore, the invention relates to methods for controlling unwanted vegetation wherein said malonamide compounds or the corresponding compositions are applied.
-
公开(公告)号:WO2022056045A1
公开(公告)日:2022-03-17
申请号:PCT/US2021/049534
申请日:2021-09-08
申请人: UNIVERSITY OF VIRGINIA PATENT FOUNDATION , LYNCH, Kevin R. , KHAREL, Yugesh , SANTOS, Webster L. , FRITZEMEIER, Russell G. , BURGIO, Ariel Louise , SHRADER, Christopher , FOSTER, Daniel
发明人: LYNCH, Kevin R. , KHAREL, Yugesh , SANTOS, Webster L. , FRITZEMEIER, Russell G. , BURGIO, Ariel Louise , SHRADER, Christopher , FOSTER, Daniel
IPC分类号: C07D205/04 , C07D207/06 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/06 , C07D211/34 , C07D211/56 , C07D241/04 , A61K31/4406 , A61K31/401 , A61P35/00 , A61P37/00
摘要: The present disclosure provides SPNS2 inhibitor compounds according to Formula (IA) and Formula (I), and their pharmaceutically acceptable salts, and/or tautomers as described in the disclosure, and the disclosure provides their pharmaceutical compositions and methods of use in therapy.
-
公开(公告)号:WO2022021841A1
公开(公告)日:2022-02-03
申请号:PCT/CN2021/076400
申请日:2021-02-09
申请人: 四川大学
IPC分类号: C07D207/16 , C07D403/12 , A61K31/4025 , A61K31/422 , A61P31/14
摘要: 公开了一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途。具体提供式(I)所示化合物、或其药学上可接受的盐、或其立体异构体、或其旋光异构体、或其同位素替代形式。该化合物能够有效抑制SARS-CoV-2 M pro活性,可以用来制备SARS-CoV-2 M pro抑制剂,阻断SARS-CoV-2病毒在患者体内的复制和转录。所述化合物在制备SARS-CoV-2 M pro抑制剂,抗SARS-CoV-2的药物,以及预防和/或治疗新型冠状病毒肺炎的药物中具有非常好的应用前景。
-
公开(公告)号:WO2022013565A1
公开(公告)日:2022-01-20
申请号:PCT/GB2021/051828
申请日:2021-07-16
IPC分类号: C07C45/00 , C07D207/16 , C07D213/81 , C07D213/82 , A61K31/12 , A61P25/00 , A61P29/00 , A61P35/00
摘要: The present invention relates to a co-crystal consisting essentially of curcumin and a co-crystal former, wherein the co-crystal former is a combination of nicotinamide and isonicotinamide, or wherein the co-crystal former is proline. The structures of the co-crystals have been elucidated and shown to contain slip planes and other structural features which provide a benefit for pharmaceutical compositions containing the co-crystals.
-
7.
公开(公告)号:WO2022008477A1
公开(公告)日:2022-01-13
申请号:PCT/EP2021/068577
申请日:2021-07-06
IPC分类号: C07D207/16 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/28
摘要: The present invention relates to 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro- pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity Formula (I) to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.
-
8.
公开(公告)号:WO2021254734A1
公开(公告)日:2021-12-23
申请号:PCT/EP2021/063893
申请日:2021-05-25
IPC分类号: C07C231/02 , A61K8/00 , A61K31/00 , A61Q19/00 , C07C233/47 , C07C233/49 , A61K2800/10 , A61K8/44 , A61K9/0048 , C07D207/16
摘要: Procédé de préparation d'un N-acyle d'acide aminé comprenant la réaction d'un acide gras et d'un acide aminé à une température supérieure ou égale à 165°C pendant au moins 1h.
-
公开(公告)号:WO2021253306A1
公开(公告)日:2021-12-23
申请号:PCT/CN2020/096709
申请日:2020-06-18
申请人: 苏州园方生物科技有限公司
发明人: 张小峰
IPC分类号: C07D207/16 , C07B2200/13
摘要: 一种DL-脯氨酸的制备方法,包括以下步骤:将L-脯氨酸和冰醋酸混合并搅拌升温至60~75℃,继续保温搅拌2~6h后蒸馏,其中,所述蒸馏的方法为:先蒸馏至无液体流出,再继续蒸馏20~40min。将蒸馏后的剩余物浓缩得到浓缩液A。将浓缩液A与异丙醇混合,搅拌至晶体析出完全,收集晶体并用异丙醇漂洗得到粗品。将粗品、活性炭和水混合并搅拌至粗品完全溶解,过滤去除活性炭,将过滤后的剩余物浓缩得到浓缩液B。将浓缩液B与异丙醇混合,搅拌至晶体析出完全,收集晶体并用异丙醇漂洗,漂洗后将晶体干燥得DL-脯氨酸。该DL-脯氨酸的制备方法工艺简单,便于工业化操作,且提高了产品的收率和质量。
-
10.
公开(公告)号:WO2021250174A1
公开(公告)日:2021-12-16
申请号:PCT/EP2021/065629
申请日:2021-06-10
申请人: EPICS THERAPEUTICS
发明人: DUTHEUIL, Guillaume
IPC分类号: C07D207/16 , A61K31/401 , A61P29/00
摘要: The present invention relates to a process of manufacturing of (2S,5R)-5-(2- chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid (1), including the preparation of (2S,5R)-methyl 5-(2-chlorophenyl)pyrrolidine-2- carboxylate hydrochloride (6.HCl) as intermediate of synthesis:
-
-
-
-
-
-
-
-
-